Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiomyopathy
Biotech
BridgeBio touts extension study data for ATTR-CM drug acoramidis
BridgeBio has presented more data for its TTR stabilizer acoramidis indicating it can become a force as a treatment for cardiomyopathy.
Kevin Dunleavy
Nov 18, 2024 3:38pm
Intellia, Alnylam post data on contrasting cardiomyopathy ideas
Nov 18, 2024 7:40am
Edgewise unveils promising early data for heart disease drug
Sep 20, 2024 4:00am
BioMarin halts preclinical gene therapy for heart condition
Aug 6, 2024 9:01am
Bayer pays $310M for Europe rights to BridgeBio's Vyndaqel rival
Mar 4, 2024 8:22am
Cytokinetics not in sale process, CEO says
Feb 28, 2024 11:25am
